Depo-Provera / Meningioma Marketing & Claimant Acquisition

The litigation landscape

The central allegation is that long-term exposure to medroxyprogesterone acetate — the synthetic progestin in Depo-Provera — promotes the growth of intracranial meningiomas, brain tumors that can require surgical resection and carry serious, life-altering consequences. Pfizer Inc. is the named manufacturer. The injury profile is severe and documentable: claimants who received the injection for an extended period and subsequently received a meningioma diagnosis, particularly those who required surgery, represent the core of the docket plaintiff firms are assembling.

For advertising purposes, this tort draws a useful parallel to the early Zantac/Ranitidine litigation cycle of 2019 — a period when proactive firms that moved quickly on paid acquisition built substantial dockets ahead of the broader market. The Depo-Provera meningioma tort shares that same characteristic: a single dominant manufacturer, a discrete and serious injury, and a claimant population that is identifiable by both product use history and medical diagnosis.

Who a campaign targets

• Primary target audience: Women who received Depo-Provera (medroxyprogesterone acetate) injections for one year or longer and have been diagnosed with an intracranial meningioma — especially those who underwent surgery to address the tumor.
• Strongest case profile: Extended use (one year or more) + confirmed meningioma diagnosis + surgical intervention. Campaigns should be structured to surface and prioritize this profile at intake.
• Borderline profile: Women with less than one year of Depo-Provera use, or those diagnosed with a meningioma who did not require surgery. Firms should define their own intake threshold for this tier — MTAA will build qualification logic accordingly.
• Geographic and demographic fit: The claimant population spans a broad age range of women who used injectable contraception, making Meta's targeting infrastructure — interest, behavioral, and lookalike audiences — well-suited to reaching them at scale.

How MTAA runs Depo-Provera / Meningioma campaigns

The creative strategy for Depo-Provera meningioma campaigns centers on the severity and specificity of the injury. Brain tumor diagnosis — particularly one requiring surgery — is a life-defining medical event, and claimants who experienced it after years of Depo-Provera use are highly motivated to understand whether they have a claim. Ad creative that leads with the injury (meningioma / brain tumor) and connects it plainly to Depo-Provera use drives strong self-identification among the right audience. This is not a tort where claimants are uncertain whether they were exposed — women who received the injection know it, and those who had brain surgery remember it. The creative job is recognition and call-to-action, not education from scratch.

On the intake side, qualification logic should be built to capture use duration and surgical history early in the funnel, allowing firms to tier leads in real time and allocate follow-up resources to the strongest case profiles. MTAA structures campaigns with intake partners or in-house intake teams in mind, ensuring that the volume generated is pre-qualified to the firm's defined criteria before it hits the phones. Given the parallels to the early Zantac cycle, firms that move now — before CPLs reflect broad market competition — are positioned to build dockets at a meaningful cost advantage.